Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Biohaven (NYSE:BHVN – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($1.56) ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Cytokinetics (CYTK – Research Report) yesterday and set a price target of ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation. Analyst Price Forecast Suggests 54.20% Upside As of January 29, 2025, the ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...

Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company’s potential treatment for a rare disease. The FDA’s ...

Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have received an average rating of “Buy” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports.

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...

N ews of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational ...